I think if Tarceva received approval for maintenance therapy in NSCLC based on a modest improvement in outcomes, then ridaforolimus should be approved for sarcoma.
Nevertheless, I've mentioned on the ARIA board before that I am nervous about its approval chances. I'm not excited about ridaforolimus' commercial potential for sarcoma either. Ponatinib is undoubtedly ARIA's crown jewel. For me, any success with ridaforolimus would be a bonus.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.